logo-loader
viewAdvaxis

Advaxis gets fast-track status for bone cancer drug

US regulators designate cancer immunotherapy group's ADXS-HER2 for fast-tracking

shutterstock_366401786.jpg
Advaxis’s core discovery – LM Technology – alters a live strain of listeria bacteria to fight bone cancer

Cancer immunotherapy group (NASDAQ:ADXS) Advaxis Inc has won fast-track status for a new bone cancer drug.

Advaxis said the US Food & Drug Administration (FDA) had granted the designation for its ADXS-HER2 treatment for osteosarcoma.

Fast-track status was conceived in 1997 to speed up development of therapies for serious or life-threatening conditions for which there are no effective treatments.

The company’s products such as ADXS-HER2 are designed to harness the body’s ability to recognize and attack bacterial infections.

Advaxis’s core discovery – LM Technology – alters a live strain of listeria mono-cytogene bacteria to generate cancer-fighting T-cells.

Chief executive Daniel O’Connor said: “There are limited therapeutic treatment options available for this patient population, with no new treatments approved in over 20 years.

“ADXS-HER2 received orphan drug designation in 2015 from the FDA and EMA for the treatment of osteosarcoma.

“We believe that with these FDA-implemented incentive programs, like fast-track designation, patients are truly the benefactors.”

Shares in Advaxis rose 6.45% to US$8.58 in morning New York trading. 

Quick facts: Advaxis

Price: 0.616 USD

NASDAQ:ADXS
Market: NASDAQ
Market Cap: $37.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it...

Admedus Ltd's (ASX:AHZ) Wayne Paterson caught up with Proactive's Andrew Scott to discuss the steps and precautions the firm's taking in the wake of the recent virus outbreak. The company's just announced the hospital discharge of the first patient following its clinical surgical aortic valve...

15 hours, 49 minutes ago

2 min read